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Abstract
Motivational symptoms such as anergia, fatigue, and reduced exertion of effort are seen in depressed people. To model this, 
nucleus accumbens (Nacb) dopamine (DA) depletions are used to induce a low-effort bias in rodents tested on effort-based 
decision-making. We evaluated the effect of the catecholamine uptake blocker bupropion on its own, and after administra-
tion of tetrabenazine (TBZ), which blocks vesicular storage, depletes DA, and induces depressive symptoms in humans. 
Male CD1 mice were tested on a 3-choice-T-maze task that assessed preference between a reinforcer involving voluntary 
physical activity (running wheel, RW) vs. sedentary activities (sweet food pellet intake or a neutral non-social odor). Mice 
also were tested on the forced swim test (FST), two anxiety-related measures (dark–light box (DL), and elevated plus maze 
(EPM)). Expression of phosphorylated DARPP-32 (Thr34 and Thr75) was evaluated by immunohistochemistry as a marker 
of DA-related signal transduction. Bupropion increased selection of RW activity on the T-maze. TBZ reduced time running, 
but increased time-consuming sucrose, indicating an induction of a low-effort bias, but not an effect on primary sucrose 
motivation. In the FST, bupropion reduced immobility, increasing swimming and climbing, and TBZ produced the opposite 
effects. Bupropion reversed the effects of TBZ on the T-maze and the FST, and also on pDARPP32-Thr34 expression in 
Nacb core. None of these manipulations affected anxiety-related parameters. Thus, bupropion improved active behaviors, 
which were negatively motivated in the FST, and active behaviors that were positively motivated in the T-maze task, which 
has implications for using catecholamine uptake inhibitors for treating anergia and fatigue-like symptoms.
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Introduction
Psychiatric pathologies such as depression are characterized 
not only by emotional and cognitive symptoms, but also by 
motivational deficiencies that lead to manifestations such as 
anergia, psychomotor slowing, fatigue, and lassitude (Stahl 
2002; Demyttenaere et al. 2005; Treadway and Zald 2011; 
Fava et al. 2014; Salamone et al. 2015; Barch et al. 2016). 
The severity of these symptoms limits long-term functional 
outcomes, producing problems with employment and social 
functions (Salamone et al. 2007; Fava et al. 2014; Rothschild 
et al. 2014; Chong et al. 2016). People with major depres-
sion have deficits in the exertion of effort, reward seeking, 
and effort-related decision-making that are not necessarily 
dependent upon alterations in the experience of pleasure 
in response to primary stimuli (Treadway and Zald 2011; 
Argyropoulos and Nutt 2013; Pizzagalli 2014; Knowland 
and Lim 2018).
Several lines of evidence point to the involvement of the 
mesolimbic dopamine (DA) system, particularly the DA 
innervation of nucleus accumbens (Nacb), in effort-related 
dysfunctions potentially related to depressive symptoms 
(Caligiuri and Ellwanger 2000; Schmidt et al. 2001; Volkow 
et al. 2001; Salamone et al. 2007, 2016, 2018). In animal 
models, the administration of the vesicular monoamine 
transporter type-2 (VMAT-2) blocker and DA-depleting 
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agent tetrabenazine (TBZ) produces effort-related motiva-
tional dysfunction, characterized by shifts in behavior from 
physically demanding options that lead to highly preferred 
reinforcers, towards low-effort ones that lead to less valued 
reinforcers (Carratalá-Ros et al. 2020, 2021; Correa et al. 
2018; López-Cruz et al. 2018; Nunes et al. 2013; Pardo et al. 
2015; Randall et al. 2012; Rotolo et al. 2019, 2020; Yang 
et al. 2020a, b; Yohn et al. 2016b, c). TBZ in humans has 
been used for the treatment of Huntington disease, and it 
has been reported to induce depressive symptoms mainly 
related to fatigue and psychomotor retardation (Frank 2009; 
Guay 2010).
Moreover, it has been shown that blockade of the DA 
transporter (DAT), which leads to increases in extracellu-
lar DA, can improve motivational symptoms in depressed 
patients (Patkar et al. 2006; Goss et al. 2013; Malhi et al. 
2016). Thus, the catecholamine uptake inhibitor bupropion 
has demonstrated efficacy to treat motivational symptoms 
in depression (Feighner et al. 1986; Kiev et al. 1994; Weihs 
et al. 2000; Papakostas 2006; Pae et al. 2007; Cooper et al. 
2014). Its main mechanism of action is to block the cat-
echolamine transporters DAT and NET (norepinephrine 
transporter), and it shows low potential to produce abuse 
in humans (Learned-Coughlin et  al. 2003; Stahl et  al. 
2004; Nutt et al. 2007) and in rodents (Mori et al. 2013). 
In addition, it has been shown that bupropion increases 
extracellular DA and DA-related signal transduction in 
Nacb (Randall et al. 2014, 2015). Considerable evidence 
indicates that enhancement of DA transmission can reverse 
effort-decision-making impairments (Salamone et al. 2007, 
2015, 2016; Mai et al. 2012; Hosking et al. 2015; Yohn et al. 
2015a, 2016b, c, d, e; Floresco et al. 2018; Rotolo et al. 
2019, 2020). Thus, in operant tasks (progressive (PROG) 
or fixed ratio (FR5) vs chow free feeding), bupropion was 
able to alleviate and reverse the effects produced by TBZ, 
increasing the effort to work in order to obtain a preferred 
food (Randall et al. 2014; Yohn et al. 2015a, 2015b, 2016b).
In evaluating effort-based decision-making processes in 
rodent models, lever pressing is the most commonly used 
work requirement (Treadway et al. 2012; Randall et al. 2014; 
Yohn et al. 2015a, b, 2016b, c). However, more whole-body 
physical activities such as rearing (Yang et al. 2020a, b), 
barrier climbing (Salamone 1994), or wheel running can be 
used as the requirement to get access to the most preferred 
reinforcer, or even as the more preferred activity (Correa 
et al. 2016, 2020). Physical activities can require high lev-
els of performance and endurance, but they also can have 
intrinsic motivational properties (Belke 2006; Belke and 
Pierce 2014). One of the most commonly studied voluntary 
physical activities in rodent models is wheel running, which 
can be performed under non-stressed conditions. Mice run 
spontaneously when given access to running wheels, and, 
depending on the strain, they can run for a total distance of 
up to 20 km per day and a total activity time of around 3 to 
7 h a day (Manzanares et al. 2019). Thus, wheel running can 
be used as the highly preferred and highly demanding choice 
in relation to other less preferred but less effort demanding 
alternatives, such as consumption of palatable food or drugs 
of abuse (Premack and Premack 1963; McMillan et al. 1995; 
Mueller et al. 1997; Cosgrove et al. 2002; Correa et al. 2016, 
2020; López-Cruz et al. 2018; Carratalá-Ros et al. 2020; 
Presby et al. 2020). However, little is known about the neural 
mechanisms involved in the decision-making processes that 
establish those preferences for vigorous physically demand-
ing behaviors.
Therefore, the present study explored the impact of 
bupropion, administered alone or in combination with the 
DA-depleting agent TBZ, on performance in the 3-choice 
T-maze task, which uses voluntary exercise in a running 
wheel as the most preferred but high effort demanding 
option in competition with less preferred but more seden-
tary options such as consumption of high-sucrose–contain-
ing food or sniffing floral odors (Carratalá-Ros et al. 2020; 
Correa et al. 2020; López-Cruz et al. 2018). Because stress 
can biphasically affect how much animals run: acute stress 
increases short-term running (Gurfein et al. 2012), while 
mild chronic stress reduces total spontaneous wheel running 
in mice (DeVallance et al. 2017), we compared the impact of 
bupropion alone or after TBZ administration, on spontane-
ous preference under non-stressful conditions (animals were 
non-food restricted, running was voluntary, and the smell 
used had demonstrated to be neutral for mice in previous 
studies (López-Cruz et al. 2018).
In addition, because aversive states such as stress and 
anxiety play a role in depression and could affect the acti-
vational component of motivated behaviors (Shafiei et al. 
2012), we assess if the present pharmacological manipula-
tions have an impact on the forced swim test (FST). This par-
adigm presents a stressful and non-escapable experimental 
setting such a deep tank full of water in which naïve rodents 
at first try to actively scape, but after a while, they give up 
and remain immobile (mainly floating) or mildly swimming 
to stay afloat (Porsolt et al. 1977; Armario and Nadal 2013). 
This immobility in the FST can be reversed by different cat-
egories of drugs, including drugs used as antidepressants 
(Porsolt et al. 1977; Lucki 1997; Gil and Armario 1998). 
However, vigorous escape-related behaviors such as climb-
ing can be also modified by antidepressant drugs (Arma-
rio et al 1988; Lucki 1997). Furthermore, there is evidence 
that active behaviors are more likely to be affected by DA 
manipulations than the traditional immobility measure (Gil 
and Armario 1998; Costa et al. 2013). Thus, TBZ increases 
immobility in mice and rats (Jang et al. 2009; Wang et al. 
2010; Carratalá-Ros et al. 2020, 2021), but also has shown 
to dose dependently produced a significant decrease in 
climbing (Carratalá-Ros et al. 2020), and bupropion has 
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antiimmobility effects in mice and rats (Yamada et al. 2004; 
Kitamura et al. 2010; Yuen et al. 2017), but also increases 
swimming and climbing (Rénéric and Lucki 1998; Hayashi 
et al. 2011; Yuen et al. 2017). Moreover, in the same ani-
mals, we evaluated anxiety-related behaviors in the dark and 
light box (DL) and the elevated plus maze (EPM).
Finally, an additional experiment studied how the most 
effective dose of bupropion on these behaviors would affect 
DA receptor–dependent metabotropic markers in Nacb using 




CD1 adult male mice (N = 148) purchased from Janvier, 
France S.A. were 8–14 weeks old (40–50 g) at the beginning 
of the study. Mice were housed in groups of three or four per 
cage, with standard laboratory rodent chow and tap water 
available ad libitum. The colony was kept at a temperature of 
22 ± 2 °C with lights on from 08:00 to 20:00 h. All animals 
were under a protocol approved by the Institutional Animal 
Care and Use committee of Universitat Jaume I. All experi-
mental procedures complied with directive 2010/63/EU of 
the European Parliament and of the Council, and with the 
“Guidelines for the Care and Use of Mammals in Neurosci-
ence and Behavioral Research”, National Research Council 
2003, USA. All efforts were made to minimize animal suf-
fering and to reduce the number of animals used.
Pharmacological agents
The catecholamine uptake inhibitor bupropion hydrochlo-
ride (Alfa Aesar, Spain) was dissolved in 0.9% saline, which 
also served as the vehicle control for these studies. Bupro-
pion was administered 30 min before tests started. Specific 
doses and times were selected from previous work in our 
laboratory using effort based choice decision-making tasks 
(Nunes et al. 2013; Randall et al. 2014; Yohn et al. 2015b) 
and from studies with the forced swim test (Yamada et al. 
2004; Kitamura et al. 2010). The VMAT-2 inhibitor tetra-
benazine (TBZ, CIMYT Quimica SL, Spain) was dissolved 
in a solution of 0.9% saline (80%) plus dimethylsulfoxide 
(DMSO 20%, final pH 5.5) and administered 120 min before 
testing. The vehicle solution of 20% DMSO and saline was 
used as the vehicle control for TBZ. Time and doses were 
selected based on previous work (Correa et al. 2018; López-
Cruz et al. 2018; Carratalá-Ros et al. 2020). All drugs were 
administered intraperitoneally (IP).
Testing procedures
All behavioral procedures started 2 h after light period onset. 
The behavioral test room was illuminated with a soft light, 
and external noise was attenuated.
T‑maze RW‑sucrose‑odor choice task
The T-maze apparatus (25 cm L × 11 cm W × 30 cm H) con-
sisted of a central area that lead to 3 arms (based on Correa 
et al. 2020, 2016; see Fig. 1). Each arm provided different 
types of stimuli. In one of them, sweet pellets (TestDietTM, 
50% sucrose, 45 mg each) were available; in another arm, 
there was a RW, and in the third arm, there was a hole with 
a cotton ball socked with a neutral non-social odor (López-
Cruz et al. 2018; Carratalá-Ros et al. 2020). Training as well 
as test sessions lasted 15 min. Mice were trained 5 days a 
week. In training phase 1, to avoid neophobia to the sweet 
tasting pellets, animals were enclosed in that arm with the 
food during 5 sessions. In training phase 2, during 2 more 
weeks, animals were given one 15-min session a day to the 
T-maze with free access to the three stimuli. Test phase 
lasted during 4 or 5 more weeks depending on the experi-
ment. For each week, there were 4 baseline days plus a test-
ing session in which animals received drug injections. Test 
sessions were videotaped and a trained observer unaware 
of the experimental condition manually registered several 
parameters. Time interacting with each of the stimuli was 
selected as the main dependent measure because it allowed 
for the evaluation of the three stimuli with the same scale. 
Time allocation is a useful measure of preference, relative 
reinforcement value, and response choice (Baum and Rach-
lin 1969). Entries into the arms (as a measure of explora-
tion) and time spent in the arms of the T-maze (as an index 
confirming proximity to the stimuli) were simultaneously 
recorded. All these measures were taken based on previous 
studies (Correa et al. 2016, 2020; López-Cruz et al. 2018; 
Carratalá-Ros et al. 2020).
Forced swim test
This paradigm has been used as a test for evaluating drugs 
with potential as antidepressants (Porsolt et  al. 1977). 
Immobility is the main dependent variable evaluated, and 
was defined as the period during which the animal remained 
motionless, making only minor movements to balance the 
body and keep the head above the water. This immobility 
response has been considered as a measure for depression 
and despair which is a very anthropomorphical way of 
understanding a switch from active to passive behavior in the 
face of an acute stressor that, in fact, is behaviorally adap-
tive and reveals coping strategies in an inescapable situation 
(Molendijk and de Kloet 2015; Armario 2021). Thus, in the 
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present group of experiments, active behaviors were also 
recorded. Swimming was recorded when animals carried 
out horizontal movements with their forepaws, leading to the 
displacement of the body throughout the swim chamber. In 
addition, we also assessed escape-related mobility behavior 
such climbing (Armario et al. 1988; Gil and Armario 1998). 
Climbing is defined as any energetic and vertical movement 
of all four limbs against the wall of the tank. Naïve mice 
were placed in a transparent cylindrical glass tank (26-cm 
high and 18-cm diameter) filled with water (14 cm) and 
maintained at a temperature of 25 °C. Water was changed 
between animals. During the 6-min test, mice were vide-
otaped from the side, and climbing, immobility, and mild 
swimming were later measured by an observer unaware of 
the experimental condition. After the test, mice were dried 
with a soft towel, put back in a box with absorbing paper 
under a warming light, and were monitored for 10 min.
Because this same animals received 7 days later the same 
doses and drug combinations and were evaluated in the anx-
iety tests, we performed correlational analysis to observe 
potential pathological traits (Armario 2021).
Dark and light box
The DL test is based on the conflict between the tendency 
to explore a novel environment and the avoidance of a 
brightly lighted open area (Blumstein and Crawley 1983). 
The DL apparatus consisted of a polypropylene chamber 
divided in two compartments by a partition containing a 
small opening (5 cm H × 5 cm W). The light compartment 
(25 cm W × 25 cm H × 25 cm L) was open, painted in white, 
and illuminated (335  lx), while the dark compartment 
(25 cm W × 25 cm H × 18 cm L) was painted in black and 
had a removable ceiling to close it. To start the test session, 
mice were individually placed in the dark chamber facing 
one corner. Test sessions were videotaped, and the latency 
of the first entry into the lit chamber, the total number of 
crosses, and the total time spent in the lit chamber were 
recorded for 5 min (procedure is based on López-Cruz et al. 
2017).
Elevated plus maze
After being in the DL box for 5 min, animals were placed in 
the EPM for 5 more minutes. The EPM consists of two open 
and two enclosed arms (65 cm L × 5 cm W) arranged in a 
plus configuration and intersecting in a central platform. It 
is made of black polypropylene and is elevated 50 cm above 
the floor. The open arms have a 1-cm border around their 
perimeter, and the closed arms have a 20-cm translucent 
wall. This anxiety paradigm measures the avoidance that 
rodents show to elevated open spaces. Under normal con-
ditions, mice spent more time and make more entries into 
the closed arms of the maze (Lister 1987). Animals were 
placed in the central platform with their head pointing at 
one enclosed arm, and they were assessed during 5 min. 
Sessions were videotaped, and a trained observer unaware 
of the experimental condition registered total time spent in 
the open arms and also total number of entries in the four 
arms as an index of locomotion. An entry into an arm was 
Fig. 1  Schematic representation 
of the three-choice T-maze task 
settings and timeline for the 
different experimental phases 
for the tetrabenazine (TBZ), 




recorded when the animal crossed with all four legs the line 
that connected that arm with the central platform (procedure 
is based on López-Cruz et al. 2017).
Immunohistochemistry for phosphorylated DA 
and c‑AMP‑related phosphoprotein‑32 kDaltons
After drug treatments, animals were anesthetized with CO2 
and transcardially perfused with 0.9% physiological saline 
for 5 min, followed by perfusion with 3.7% formaldehyde 
for 5 min, and then brains were extracted. Tissue was fixed 
in 3.7% formaldehyde overnight and moved to 30% sucrose 
cryo-protectant. Then 40-um sections were cut using a 
cryostat. To measure the immunoreactivity to phospho-
rylated DA and c-AMP-regulated phosphoprotein 32 kDa 
(pDARPP-32), nonspecific binding sites were blocked with 
a solution of 3% H202 for 30 min at room temperature fol-
lowing then with 1% bovine serum albumin and 0.1% Triton 
X-100 in PBS for 1 h at room temperature. Phosphorylated 
DARPP-32 immunoreactivity was visualized with a poly-
clonal rabbit antibody for pDARPP-32 phosphorylated at 
threonine 34 residue (Thr34, 1:1000; Santa Cruz Biotech-
nology) or polyclonal rabbit antibody for pDARPP-32 phos-
phorylated at threonine 75 residue (Thr75, 1:500, Santa Cruz 
Biotechnology). These antibodies were dissolved in solu-
tions that also contained 0.1% bovine serum albumin and 0.1 
Triton X-100 in PBS for 24 h incubation on a rotating shaker 
at 4 °C. After the primary antibody treatment, the sections 
were rinsed in PBS (3 times for 5 min) and incubated in the 
secondary antibody, anti-rabbit HRP conjugate envision plus 
(DAKO) for 1 h and 30 min on a rotating shaker at room 
temperature. Finally, sections were washed and rinsed for 
3–5 min in 3,3’ diaminobenzidine chromogen. The sections 
were then mounted to gelatin-coated slides, air dried, and 
coverslipped using Eukitt quick-hardening (Sigma-Aldrich) 
as a mounting medium. The tissue was then examined by 
light microscopy.
Quantification of the number of cells that express immu-
noreactivity for pDARPP-32 (Thr34) and pDARPP-32 
(Thr75) in the Nacb core was performed by photographing 
the sections with a 20 × (0.125  mm2/field) objective (Eclipse 
E600; Nikon) upright microscope equipped with a Leica 
DFC 450C camera (Leica Microsystems) and captured 
digitally using LASX software. Cells that were positively 
labeled for pDARPP-32 (Thr34) and pDARPP-32 (Thr75) 
were quantified with ImageJ software (version 1.51) and 
a macro written to automate particle counting within the 
region of interest. The size of the region of interest was 
1000 × 1000 um. For each animal, cell counts were at levels 
that correspond to 0.70–1.70 mm anterior to bregma (Paxi-
nos and Franklin 2004) bilaterally from at least three sec-
tions and counts were averaged across slides and sections.
Western blotting for phosphorylated DA and c‑AMP 
related phosphoprotein‑32 kDaltons
We further analyzed phosphorylation of DARPP-32 at the 
Thr75 using an additional biochemical technique and a dif-
ferent primary antibody for pDARPP-32(Thr75) to exclude 
lack of sensitivity of the method as the cause of the nega-
tive immunohistochemical results. After drug treatments, 
animals were anesthetized with  CO2 and were decapitated, 
and brains were extracted. Fresh striatal tissue samples were 
homogenized in ice-cold lysis buffer (130 Mm NaCl, 20 Mm 
Tris–Hcl at Ph 8.0, and 1% Nonidet P40), containing pro-
tease inhibitors (10 ug/ml of aprotinin, 20ug/ml of leupe-
tine, and 1 Mm PMSF) as well as phosphatase inhibitors 
(10 Mm NaF, 1 Mm sodium orthovanade and 10 Mm DTT). 
Homogenates were centrifuged at 13,000 rpm for 15 min at 
4 °C. Aliquots of supernatants were collected and used Brad-
ford quantification of total protein. Every sample was boiled 
for 3 min for protein denaturation. Equal amounts (30ug) 
of striatum protein samples were separated by 12.5% SDS-
PAGE and transferred to nitrocellulose membrane (Bio-rad) 
for 90 min at 30 V. Filtering membranes were incubated 
in 5% of bovine serum albumin (BSA, Sigma-Aldrich) dis-
solved in TBS-T (Tris Base 200 Mm and 5 M NaCl) con-
taining 0.1% Tween 20, and then incubated overnight at 
4 °C with polyclonal rabbit anti-DARPP32-Thr75 antibody 
(1:500, cell signaling). Membranes were probed with anti-
actin polyclonal antibody (1:500, Abcam), as an internal 
standard for protein quantification. After rinses with TBS-T 
buffer, membranes were incubated with goat anti-rabbit IG 
secondary antibody coupled to HRP (1:20,000, Bio-rad) dur-
ing 1 h and developed by enhanced chemiluminescence sys-
tem (1:40, ThermoFisher Scientific). The membranes were 
exposed to Image Quant LAS 4000 (Leica). The relative 
densities of brands were analyzed using ImageJ software. 
Every sample was replicated at least twice to ensure the 
reproducibility of the method.
Statistical analyses
Normally distributed data (according to Kolmogorov-
Smirnov test) in the T-maze experiment followed a within 
groups design. Thus, data were analyzed by repeated meas-
ures ANOVA. Normally distributed and homogenous data 
for the FST, DL, EPM, and the biochemical experiments 
employed a between groups design, and data were analyzed 
by one-way ANOVA. When the overall ANOVA was signifi-
cant, non-orthogonal planned comparisons using the overall 
error term were used to compare each treatment with the 
vehicle control group (Keppel 1991). For these comparisons, 
α level was kept at 0.05 because the number of comparisons 
was restricted to the number of treatments minus one. To 
evaluate the relation between the behaviors in the FST with 
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the behaviors in the DL and EPM paradigms done in the 
same mice, Pearson r correlational coefficient was used. All 
data were expressed as mean ± SEM, and significance was 
set at p < 0.05. STATISTICA 7.0 software was used.
Results
Effect of bupropion on preference for reinforcers 
as measured in the 3‑choice‑T‑maze task
Animals (N = 14) received a dose of BUP (0.0, 5.0, 10.0, and 
15.0 mg/kg) once a week in a randomly varied order. The 
T-maze paradigm requires a baseline performance of two 
weeks before tests start, and that performance was main-
tained across weeks, thus allowing for a repeated measures 
design. Repeated measures ANOVA showed that bupropion 
did not produce a significant effect on time spent eating the 
sucrose pellets (F(3,39) = 2.38, p = 0.08), or time sniffing 
the neutral odor (F(3,39) = 0.45, p = 0.71) (Fig. 2A and 
C). However, bupropion significantly increased time run-
ning in the RW (F(3,39) = 3.26, p < 0.05). Planned com-
parisons revealed that all doses of bupropion (5.0, 10.0, and 
15.0 mg/kg) significantly increased time running in the RW 
compared to the vehicle group (p < 0.05 for the two lower 
doses and p < 0.01 for the highest one; Fig. 2B). Moreo-
ver, repeated measures ANOVA also showed a significant 
effect of bupropion on time spent in the RW compartment 
(F(3,39) = 4.35, p < 0.01), and time spent in the food com-
partment (F(3,39) = 3.92, p < 0.01). Planned comparisons 
showed that all doses of bupropion increased time spent 
in the RW compartment in comparison with the vehi-
cle group (10.0 mg/kg p < 0.05, and 5.0, and 15.0 mg/kg 
p < 0.01). Similarly, bupropion-treated mice spent less time 
in the sucrose pellet compartment in comparison with the 
vehicle group (10.0 mg/kg p < 0.05, and 5.0, and 15.0 mg/
kg p < 0.01). However, there was no significant effect of 
bupropion on time spent in the neutral odor compartment 
(F(3,39) = 1.78, p = 0.16) (Fig. 2E). Finally, bupropion did 
not produce significant differences in the number of entries 
into the food compartment (F(3,39) = 1.39, p = 0.42), entries 
to the RW compartment (F(3,39) = 1.39, p = 0.25), or entries 
to the neutral odor compartment (F(3,39) = 0.13, p = 0.93) 
(Fig. 2D).
Effect of bupropion in combination with TBZ 
on preference for reinforcers as measured 
in the 3‑choice‑T‑maze task
A new group of mice (N = 13) received TBZ (8.0 mg/kg) 
and 90 min later (30 min before being placed in the T-maze 
during 15 min), they received a dose of BUP (5.0, 10.0, 
and 15.0 mg/kg, randomly varied order, repeated meas-
ures design). Thus, animals received one drug combination 
(Veh-Veh, TBZ-Veh, TBZ-BUP 5.0, TBZ-BUP 10.0, and 
TBZ-BUP 15.0 mg/kg) every week during 5 weeks in a 
random varied order. Repeated measures ANOVA resulted 
in a significant effect of treatment on time spent eating the 
sucrose pellets (F(4,48) = 4.60, p < 0.01). Planned compari-
sons revealed TBZ-Veh increased the time animals spent eat-
ing sucrose pellets (p < 0.05) compared to Veh-Veh, and all 
doses of bupropion were able to decrease significantly time 
consuming the food (p < 0.01) in comparison with the TBZ-
Veh condition (p < 0.01) (Fig. 3A). In addition, repeated 
measures ANOVA also show a significant effect of treat-
ment on time running in the RW (F(4,48) = 3.06, p < 0.05). 
Planned comparisons revealed that the TBZ-Veh condition 
significantly reduced time running in the RW (p < 0.05) in 
Fig. 2  Effect of bupropion 
(vehicle, 5, 10, and 15 mg/kg) 
on time eating (A), time running 
(B), time sniffing (C), entries 
into compartments (D), and 
time spent in each compartment 
(E) of the T-maze task assessed 
during 15 min. Bars represent 
mean ± S.E.M. of accumulated 
seconds or number of entries. 
*p < 0.05, **p < 0.01 signifi-
cantly different from vehicle
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comparison with the Veh-Veh condition. The TBZ-BUP 
10.0 mg/kg treatment reversed this effect, increasing time 
running in the RW when compared to the TBZ-Veh con-
dition (p < 0.01) (Fig. 3B). Finally, the repeated measures 
ANOVA did not show a significant effect on sniffing the 
neutral odor F(4,48) = 0.54, p = 0.70) (Fig. 3C).
Repeated measures ANOVA did not show a significant 
effect of treatment on time spent in the RW compartment 
(F(4,48) = 1.93, p = 0.11), or time spent in the neutral odor 
compartment (F(4,48) = 0.91, p = 0.46) (data are shown in 
Fig. 3E). However, there was a significant effect on time 
spent in the food compartment (F(4,48) = 4.04, p < 0.01), 
with planned comparisons showing that TBZ-Veh–treated 
mice spent more time in the food compartment in com-
parison with the Veh-Veh group (p < 0.05), and all groups 
treated with TBZ plus bupropion (5.0, 10.0, and 15.0 mg/
kg) reversed this effect when compared with the TBZ-Veh 
treatment (p < 0.01). Finally, repeated measures ANOVA 
for the dependent variable entries in compartment did not 
show a significant effect of treatment on total number of 
entries to the food compartment (F(4,48) = 1.48, p = 0.22), 
or to the neutral odor compartment (F(4,48) = 2.48, p = 0.06) 
(Fig. 2D). However, there was a significant effect on total 
entries to the RW compartment (F(4,48) = 2.92, p < 0.05), 
and planned comparisons showed that TBZ-BUP 10.0 mg/
kg treated mice decreased number of entries to the RW 
compartment in comparison with the Veh-Veh treatment 
(p < 0.01).
Effect of bupropion on FST performance
Naïve animals (N=40) received vehicle or one dose of 
BUP (5.0, 10.0 or 15.0 mg/kg) and 30 min after the injec-
tion were placed in the FST during 6 minutes. Mice were 
exposed only once to the FST since behavioral habitua-
tion develops in one session. The one-way ANOVA for the 
different dependent variables showed a significant effect 
on time spent immobile (F(3,36) = 7.27, p < 0.01), time 
spent swimming (F(3,36) = 5.47, p < 0.01), and time spent 
climbing (F(3,36) = 2.77, p < 0.05) in the FST. Planned 
comparisons revealed that all the groups that received 
bupropion (5.0, 10.0, and 15.0 mg/kg) displayed signifi-
cantly less time immobile (p < 0.01), and spent more time 
swimming (p < 0.05 for 10.0 mg/kg and p < 0.01 for 5.0 
and 15.0 mg/kg) in comparison with the vehicle group. 
However, only the group that received 10.0  mg/kg of 
bupropion displayed more time climbing than the vehicle 
group (p < 0.01) (Fig. 4A).
Effect of bupropion in combination with TBZ on FST 
performance
Naïve mice (N = 35) received Veh-Veh or TBZ (8.0 mg/kg)-
Veh or Veh-BUP (10.0 mg/kg).
A series of one-way ANOVA showed a significant effect 
of treatment on immobility (F(2,32) = 13.98, p < 0.01), 
swimming (F(2,32) = 7.65, p < 0.01), and climbing 
(F(2,32) = 4.56, p < 0.01). Planned comparisons revealed 
that TBZ-Veh–treated mice spent more time immobile 
(p < 0.01) and less time swimming and climbing (p < 0.05) in 
comparison with the Veh-Veh group. Moreover, bupropion 
was able to reverse these effects, and mice that received the 
combination of TBZ (8.0 mg/kg) plus bupropion (10.0 mg/
kg) spent less time immobile and increased time swimming 
and climbing (all p < 0.01) in comparison with TBZ-Veh 
treated mice (Fig. 4B).
Fig. 3  Effect of TBZ (vehicle 
or 8 mg/kg) plus bupropion 
(vehicle, 5, 10, and 15 mg/kg) 
combination on time eating (A), 
time running (B), time sniffing 
(C), entries into compartments 
(D), and time spent in each 
compartment (E) of the T-maze 
task assessed during 15 min. 
Bars represent mean ± S.E.M. of 
accumulated seconds or number 
of entries. *p < 0.05, **p < 0.01 
significantly different from Veh-




Effect of bupropion on anxiety parameters 
as measured in the DL and EPM paradigms
Mice previously tested in experiment 3.3 (N = 40) received 
1 week later a second dose of the same treatment (vehicle 
or BUP 5.0, 10.0, or 15.0 mg/kg), and 30 min after injec-
tion, they were placed in the DL box for 5 min. Imme-
diately after this test, they were placed in the EPM for 
5 more minutes. Mice were exposed only once to both 
paradigms, since behavioral habituation develops in one 
session. The one-way ANOVA for the different dependent 
variables in the anxiety paradigms did not show significant 
effects of bupropion on time spent in the illuminated arena 
(F(3,37) = 0.74, p = 0.53) or total of crosses between the lit 
chamber and the dark chamber (F(3,37) = 0.27, p = 0.84) 
of the DL box (Table 1). Moreover, although the low dose 
of bupropion tended to reduce time in the open arms of 
the EPM paradigm, the overall ANOVA did not reached 
statistical significance (F(3,33) = 2.34, p = 0.09). However, 
there was a significant effect on total number of entries to 
all arms (F(3,33) = 6.23, p < 0.01) in the EPM. Planned 
comparisons showed that the highest dose of bupropion 
(15.0 mg/kg) increased significantly total of entries to all 
arms of the EPM (p < 0.01) in comparison with the vehicle 
group.
Further correlational analysis between results in the FST 
and in the DL and EPM indicate that among the vehicle 
group, there is a positive and statistically significant correla-
tion between time climbing (r = 0.6253, p < 0.05) on the one 
hand, and time swimming (r = 0.4588, p < 0.05) in the FST 
with time in the lit chamber of the DL box, indicating that 
those animals less prone to give up escaping are also more 
willing to get expose to anxiogenic stimuli. Accordingly, at 
the lower dose of BUP (5 mg/kg), there was a significant but 
negative correlation between immobility time (r =  − 0.7490, 
p < 0.05) with time in the open arms suggesting that animals 
that spent more time in a passive state were animals that 
spent less time in an anxiogenic situation.
Effect of bupropion in combination with TBZ 
on anxiety parameters as measured in the DL 
and EPM paradigms
Mice previously tested in the FST in experiment 3.4. (N = 35) 
received the same treatment combination of Veh-Veh or TBZ 
(8.0 mg/kg)-Veh or Veh-BUP (10.0 mg/kg) 1 week later. The 
one-way ANOVA did not show any significant effect of the 
treatment on time spent in the lit chamber of the DL box 
(F(2,28) = 0.35, p = 0.70), but the treatment produced a sig-
nificant effect on the total of crosses between compartments 
Fig. 4  Effect of bupropion (vehicle, 5, 10, or 15  mg/kg) (A) and 
TBZ plus bupropion combination (Veh-Veh, TBZ-Veh, or TBZ-
BUP 10  mg/kg) (B) on duration of immobility, swimming, and 
climbing behavior in the FST assessed during 6 min. Bars represent 
mean ± S.E.M. of accumulated seconds. *p < 0.05, **p < 0.01 signifi-
cantly different from vehicle or Veh-Veh. ##p < 0.01 significantly dif-
ferent from TBZ-Veh
Table 1  Effect of bupropion on 
mice behavior in the dark and 
light box (DL) and elevated plus 
maze (EPM). Mean (± SEM) 
seconds or counts in 5 min. 
**p < 0.01 significantly different 
from vehicle
Bupropion (mg/kg)
Vehicle 5 10 15
DL box
  Time in the lit chamber (sec) 128.8 ± 8.6 117.8 ± 13.1 116.9 ± 10.1 106.3 ± 12.8
  Crosses between compartments 27.0 ± 2.3 25.4 ± 2.8 24.8 ± 4.0 28.9 ± 4.5
EPM
  Time in open arms (sec) 83.6 ± 11.8 49.3 ± 10.8 82.8 ± 9.8 60.5 ± 7.4
  Entries to all arms 17.6 ± 2.3 13.0 ± 2.2 17.5 ± 2.5 27.0 ± 1.1**
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(F(2,28) = 5.57, p < 0.01) of the DL box. Planned compari-
sons revealed that the TBZ-Veh group (p < 0.01) and the 
TBZ-BUP (10.0 mg/kg) group (p < 0.05) were significantly 
different from the Veh-Veh group (Table 2). The one-way 
ANOVA for the variables evaluated in the EPM showed that 
the treatment produced no significant effect on time spent 
in the open arms (F(2,26) = 2.70, p = 0.08), although it pro-
duced a significant effect on the total number of entries to all 
arms (F(2,26) = 6.67, p < 0.01). Planned comparisons indi-
cated that both groups treated with TBZ showed reduced 
locomotion, TBZ-Veh (p < 0.01) and TBZ-BUP 10.0 mg/kg 
(p < 0.05) compared to the Veh-Veh group.
The Pearson correlational coefficient analysis dem-
onstrated that there was a significant positive correlation 
between time climbing (r = 0.6154, p < 0.05) and time in 
the lit chamber of the DL box in the group that received the 
drug combination TBZ-BUP (10 mg/kg).
Effect of bupropion in combination with TBZ 
on DARPP‑32 phosphorylation patters in Nacb 
as measured by immunohistochemistry
Naïve mice (N = 21) received Veh-Veh, TBZ-Veh, Veh-BUP 
10.0 mg/kg, or TBZ-BUP 10.0 mg/kg 2 h before perfusion. 
The one-way ANOVA showed an overall effect of treat-
ment on pDARPP-32(Thr34) in Nacb core (F(3,17) = 9.36, 
p < 0.01). Planned comparisons revealed that the adminis-
tration of TBZ-Veh significantly increased expression of 
phosphorylated DARPP-32(Thr34) in Nacb core in com-
parison with the Veh-Veh group (p < 0.01). TBZ-BUP treat-
ment reduced pDARPP-32(Thr34) compared to TBZ-Veh 
(p < 0.01) and also compared to Veh-Veh group (p < 0.05) 
(Fig. 5A). The one-way ANOVA showed that there was no 
significant effect of treatment on pDARPP-32(Thr75) in 
Nacb core (F(3,17) = 0.52, p = 0.66) (Fig. 5B).
Effect of TBZ on pDARPP‑32(Thr75) levels in ventral 
striatum as measured by Western blot
Naïve mice (N = 25) received Veh-Veh, TBZ-Veh, Veh-BUP 
10.0 mg/kg, or TBZ-BUP 10.0 mg/kg 120 min before brain 
extraction. The one-way ANOVA did not show an overall 
effect of treatment on pDARPP-32(Thr75) when analyzed 
by Western blotting either (F(3,21) = 0.62, p = 0.60) (Fig. 6).
Discussion
The current studies examined the ability of the catechola-
mine uptake inhibitor bupropion to produce an effect on 
selection of reinforcement as assessed in a novel 3-choice-
T-maze-task that provides information about the choice 
between a highly active physical activity (RW) vs. other 
sources of reinforcement that could be obtained with little 
effort. Those studies were compared with additional experi-
ments that examined how bupropion was able to modulate 
immobility and behavioral activation in the FST, a classi-
cal paradigm that can evaluate how drugs used as antide-
pressants potentiate behaviors to scape a stressful unescap-
able environment. Moreover, we also assessed if the same 
pharmacological manipulations have an impact on anxiety-
related parameters as measured by performance in the DL 
box and EPM paradigm. In addition, in order to characterize 
the ability of bupropion to alleviate fatigue-related behav-
ioral activation impairments, we used the VMAT-2 inhibi-
tor TBZ (8.0 mg/kg), since this drug has been reported to 
induce motivational symptoms such as anergia or fatigue 
in people (Frank 2009; Guay 2010; Chen et al. 2012), as 
well as behavioral activation impairments in classical animal 
models such as the FST or the tail suspension test (Frank 
2009; Wang et al. 2010; Carratalá-Ros et al. 2020, 2021), 
and in effort-related decision-making tasks (López-Cruz 
et al. 2018; Nunes et al. 2013; Randall et al. 2014; Rotolo 
et al. 2020, 2019; Yang et al. 2020b; Yohn et al. 2016b; 
Carratalá-Ros et al. 2020, 2021).
Bupropion is a catecholamine uptake inhibitor that is 
commonly prescribed as an antidepressant (Dwoskin et al. 
2006; Papakostas 2006; Nutt et al. 2007). Bupropion blocks 
DAT and NET, and as a result of its DAT inhibition, it 
increases extracellular DA levels and markers of post-synap-
tic DA-related signal transduction (Hudson et al. 2012; Ran-
dall et al. 2015). In humans, bupropion is able to partially 
alleviate motivational symptoms such as anergia, fatigue, 
and psychomotor retardation commonly seen in depression 
Table 2  Effect of TBZ and BUP 
combination on mice behavior 
in the dark and light (DL) box 
and elevated plus maze (EPM). 
Mean (± SEM) seconds or 
counts in 5 min. *p < 0.05, 
**p < 0.01 significantly different 
from Veh-Veh
Veh-Veh TBZ-Veh TBZ-BUP 10 mg/kg
DL box
  Time in the lit chamber (sec) 125.6 ± 6.2 117.1 ± 11.5 111.3 ± 13.8
  Crosses between compartments 23.6 ± 1.7 12.6 ± 1.5** 17.2 ± 2.2*
EPM
  Time in open arms (sec) 73.3 ± 17.4 100.5 ± 14.3 61.0 ± 8.7
  Entries to all arms 19.0 ± 1.4 10.6 ± 1.6** 13.9 ± 1.3*
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Fig. 5  Effect of treatment (Veh-Veh, TBZ-Veh, Veh-BUP, or TBZ-
BUP) on number of cell counts positive for pDARPP-32-(Thr34) 
and pDARPP-32(Thr75) immunoreactivity on Nacb core. Upper left: 
Diagram showing the effect of TBZ on DARPP-32 phosphorylation 
in D2-receptor containing cells, and coronal section with bregma 
coordinates showing location of the brain area for immunohisto-
chemistry taken from Paxino and Franklin’s mouse atlas. TBZ, which 
depletes DA, increases D2-receptor stimulation by increasing cyclic 
adenosine monophosphate (c-AMP) production and protein kinase 
A (PKA) activity yielding to the increase of the dephosphorylation 
of pDARPP-32(Thr34) and no change or a decrease in the phospho-
rylation of pDARPP-32(Thr75) by blocking the protein phosphatase 
(PP1) (based on results from Bateup et al. 2009; Nunes et al. 2013; 
López-Cruz et  al. 2018). Bottom left: photomicrographs of individ-
ual representative brain sections. Right: mean ± S.E.M of number of 
pDARPP-32-(Thr34) and pDARPP-32-(Thr75) counts in a  100um2 
ROI. *p < 0.05, **p < 0.01 significantly different from Veh-Veh. 
##p < 0.01 significant differences from TBZ-Veh
Fig. 6  Effect of treatment 
(Veh-Veh, TBZ-Veh, Veh-
BUP, or TBZ-BUP) on 
pDARPP-32 (Thr75) in ventral 
striatum. Data are expressed as 
mean ± S.E.M of density units 
of pDARPP-32 (Thr75). Lower 
and right part: representative 
Western blots showing two 
bands corresponding to actin 
(molecular weight of 42 kDa) 
and pDARPP-32(Thr75) 
(molecular weight of 32 kDa). 
Each line contains 30ug of ven-
tral striatum homogenates taken 
as tissue punctures represented 
in the coronal brain sections
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(Rampello et al. 1991; Stahl et al. 2004; Demyttenaere et al. 
2005; Pae et al. 2007).
In our experiments, mice were tested on the T-maze task, 
a paradigm that allows animals to freely choose between 3 
different non-aversive activities. With this task, animals can 
choose between a highly preferred reinforcer that requires 
a high degree of vigor (running in a RW), approaching and 
consuming a palatable reinforcer (50% sucrose pellets) that 
is also preferred in contrast to other types of foods (Nunes 
et al. 2013), or doing a more sedentary activity (sniffing 
a floral odor (López-Cruz et al. 2018; Carratalá-Ros et al. 
2020). Under basal conditions, mice usually spent most of 
the time engaged in the preferred reinforced activity (the 
RW), secondly, spent their time eating the sucrose pellets, 
and the least preferred reinforcer was consistently the non-
social odor (López-Cruz et al. 2018; Carratalá-Ros et al. 
2020). In the present studies, although the baseline prefer-
ence for the RW was already high, administration of bupro-
pion was able to significantly increase time spent running 
in comparison with the vehicle group, and also increased 
time spent in the RW compartment. This effect was paral-
leled by a mild reduction in preference for sucrose that was 
significant in terms of time spent in the food compartment 
(Fig. 2E), but there was no impact on the least preferred 
reinforcer (the odor). These doses of bupropion did not seem 
to affect ambulation in the T-maze as there was no change in 
number of crosses between compartments.
Our results are in accordance with previous studies in 
which the administration of different doses of bupropion in 
rats shifted choice behavior, increasing the tendency to work 
by lever pressing for food in a highly demanding task (i.e., 
progressive ratio (Bruijnzeel and Arkou 2003; Randall et al. 
2015). Bupropion-treated rats increased work output in order 
to obtain preferred high carbohydrate food pellets, and they 
decreased the consumption of concurrently available chow 
that is much less preferred (Randall et al. 2015). However, 
in order to improve lever pressing performance, bupropion 
had to be administered at higher doses (20 and 40 mg/kg; 
Randall et al. 2015) than the ones used in the present stud-
ies. It is possible that higher doses of bupropion alone would 
have also increase time in the RW to a higher degree show-
ing a sharper dose response curve, but RW time is very high 
under basal conditions, and our bupropion doses (5–15 mg/
kg) already elevated performance to 600 s out of 900 s that 
is the total duration of the test.
Other more selective DAT inhibitors such as GBR12909, 
PRX-14040, lisdexamfetamine, MRZ-9547, S-CE-123, 
S-CE-158, and CT-005404 also produced a significant 
increase in lever pressing in rats tested on PROG/chow 
choice tasks, and decreased intake of freely available but less 
preferred chow (Sommer et al. 2014; Yohn et al. 2016a, b, 
d, e; Rotolo et al. 2019, 2020). In addition, DAT knockdown 
mice also were shown to increase the tendency to work for 
a food reward in a concurrent choice task (Cagniard et al. 
2006).
In our studies, bupropion also showed activating effects 
in mice tested under aversive conditions, decreasing pas-
sive behaviors and increasing active behaviors such as swim-
ming and climbing tested in the FST. Previous studies have 
reported similar effects of bupropion in mice and rats tested 
on traditional immobility measures in paradigms such as the 
tail suspension test and the FST (Yamada et al. 2004; Bourin 
et al. 2005; Kitamura et al. 2008, 2010; Hufgard et al. 2017). 
However, climbing (or struggling to do so in order to scape 
a stressful and unescapable situation) has been assessed in 
relatively few studies involving bupropion (Rénéric and 
Lucki 1998; Hayashi et al. 2011). Consistent with the present 
results, in those studies, bupropion increased the time that 
mice (Hayashi et al. 2011) and rats (Rénéric and Lucki 1998) 
spent climbing in the FST but at higher doses (30–60 mg/kg) 
than the ones used in the present results. The maintenance of 
vigorous and persistent active responding (Gil and Armario 
1998) in order to escape is related to DA transmission, and 
studies that use DA antagonists or DA reuptake inhibitors 
show a decrease or increase respectively on the output of 
active behaviors in the FST (Yamada et al. 2004; Kitamura 
et al. 2010; Li et al. 2015).
Previous studies from our laboratory have demonstrated 
the anergia-inducing effects of the DA-depleting agent TBZ 
in effort-based decision-making tasks such as the present 
T-maze RW-choice task (López-Cruz et al. 2018; Carratalá-
Ros et al. 2020, 2021), the T-maze barrier-choice task (Yohn 
et al. 2015a, b; Correa et al. 2018), and also in operant pro-
cedures with different ratio requirements (PROG/chow tasks 
and FR/chow; Nunes et al. 2013; Randall et al. 2014; Rotolo 
et al. 2020, 2019; Yohn et al. 2016b). Those effects of TBZ 
were not due to changes in appetite, food preference, or food 
reactivity, and did not mimic the effects of reinforcer devalu-
ation (Carratalá-Ros et al. 2020; Correa et al. 2018; Nunes 
et al. 2013; Pardo et al. 2015; Randall et al. 2014; Yang 
et al. 2020b). In the present studies, we used a dose of TBZ 
(8.0 mg/kg) that has been shown to be effective in mice for 
depleting ventral striatal DA (López-Cruz et al. 2018) and 
shifting behavior towards sedentary sources of reinforce-
ment (Carratalá-Ros et al. 2020, 2021; Yang et al. 2020b). 
TBZ-treated mice had significantly reduced time running in 
the RW and shifted their behavior towards spending more 
time doing sedentary activities (consuming sucrose pellets) 
than under the vehicle condition. Bupropion was able to 
reverse the TBZ-induced bias away from RW activity. In 
fact, co-administration of 10.0 mg/kg of bupropion to TBZ-
treated animals produced a significant reversal of the effects 
of TBZ, as indicated by a total reversal of the effect of TBZ 
on time running in the RW, and also decreased time con-
suming sucrose. In addition, animals exit less times the RW 
compartment. These results are in accordance with previous 
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studies, in which the administration of these same doses of 
bupropion to rats alleviated with TBZ-induced anergia in 
operant procedures such as PROG/chow tasks and FR5/
chow tasks (Nunes et al. 2013; Randall et al. 2014), as well 
as the T-maze barrier-climbing task (Yohn et al. 2015a). 
In addition, the most effective dose of bupropion (10.0 mg/
kg) in the T-maze RW task, and the one that had improved 
climbing in the FST, also reversed immobility induced by 
TBZ and restored swimming and climbing to normal levels 
in TBZ-treated mice. Consistent with the present results, 
bupropion was able to decrease immobility time in VMAT-2 
mutant mice evaluated in the FST (Fukui et al. 2007).
None of these activating effects of bupropion, either when 
administered alone or in combination with TBZ, seems to 
be due to anxiolytic actions, since there were no changes in 
anxiety measures in the DL box or in the EPM (Tables 1 and 
2) in the dose range tested. Similar doses of bupropion in 
adult mice had previously been demonstrated not to have an 
impact on anxiety-related parameters evaluated in the EPM 
paradigm (Carrasco et al. 2004, 2013; Redolat et al. 2005a, 
b). Nevertheless, these doses did have effects on motor 
activity in mice (Redolat et al. 2005b), and because cross-
ings in the EPM also are sensitive to the locomotor actions 
of bupropion (Carrasco et al. 2004), we analyzed crosses 
between compartments in the DL box and entries to all arms 
in the EPM, as indices of changes in locomotion. Thus, the 
highest dose of bupropion used in the present experiments 
(15.0 mg/kg) did increase locomotion in terms of total of 
entries to all arms in the EPM paradigm, and TBZ decreased 
total crosses between compartments in the DL box and total 
of entries to the EPM paradigm. Bupropion at 10.0 mg/kg 
was not able to reverse this effect in TBZ-treated animals. 
Thus, none of the doses used in the present experiments 
seems to modulate anxiety-related behaviors, although some 
of them can affect locomotion in these paradigms, an effect 
that was not seen in terms of total number of crosses in the 
T-maze.
All these results seem consistent with the well know func-
tions of Nacb DA, which has been reported to have a key role 
in the regulation of voluntary locomotion, response vigor, 
and effort-related aspects of motivated behavior (Salamone 
and Correa 2002, 2012). Bupropion, which blocks both 
DAT and NET, increased extracellular DA levels in Nacb as 
measured by microdialysis (Randall et al. 2015), and also 
increased expression of the postsynaptic signal transduc-
tion marker DARPP-32, which is phosphorylated at different 
sites depending on the type of DA receptor that is activated 
(Svenningsson et al. 2002; Bateup et al. 2009; Randall et al. 
2015). In contrast, TBZ reduced both tissue and extracel-
lular DA levels (López-Cruz et al. 2018; Nunes et al. 2013; 
Yang et al. 2020b), and produced a pattern of phosphoryl-
ated DARPP-32 effects that is consistent with a reduction of 
post-synaptic DA signaling (López-Cruz et al. 2018; Nunes 
et al. 2013; Randall et al. 2015). In the present studies, TBZ 
significantly increased pDARPP-32(Thr34) in Nacb core 
compared to vehicle treated mice, and this effect of TBZ 
was reversed by bupropion (10.0 mg/kg). Previous studies 
with rats have shown that low doses of TBZ preferentially 
reduced levels of striatal DA compared to its effects on NE 
and 5-HT (Pettibone et al. 1984; Tanra et al. 1995), and that 
the effects of TBZ on effort-based choice are reversed by 
selective DAT inhibitors but not by inhibitors of NET or 
5-HT transport (Yohn et al. 2016c, e; Rotolo et al. 2019, 
2020, 2021). Nevertheless, in the present mouse studies, a 
possible role for NE cannot be ruled out, and recent research 
indicates that NE also plays a role in effort-based choice, 
especially exertion of effort based on force output (Varazzani 
et al. 2015; Borderies et al. 2020).
In the present studies with mice, TBZ did not affect 
phosphorylation of DARPP-32 at threonine 75 (pDARPP-
32(Thr75)) in Nacb core, using different antibodies and 
using two different techniques, immunoblotting and immu-
nohistochemistry. These results seem to differ from pre-
vious studies using immunohistochemical techniques in 
rats, in which TBZ increased both phosphorylated forms 
of DARPP-32 (Thr34 and Thr75) in Nacb core in different 
groups of neurons containing different type of DA receptors; 
pDARPP-32 (Thr34) increases in D2 containing neurons, 
while pDARPP-32 (Thr75) does so in D1 containing neu-
rons (Nunes et al. 2013). Nevertheless, these findings are 
in line with previous results in mice in which Western blot-
ting methods were used; TBZ only produced an increase on 
phosphorylation of DARPP-32(Thr34) but not on DARPP-
32(Thr75) in ventral striatum (López-Cruz et al. 2018). 
The effect of TBZ only on DARPP-32(Thr34) and not on 
DARPP-32(Thr75) could be explained by differences in the 
distribution pattern of DA receptors in the dorsolateral–ven-
tromedial striatum of mice (Fukuda 2009; Miyamoto et al. 
2018). Generally, the increase of DARPP-32(Thr75) is 
thought to be the result of an increase of D1 receptor stimu-
lation in substance P positive neurons. However, it seems the 
dorsolateral and ventrolateral domains of the rostral striatum 
of mice have low proportion of D1 receptors demonstrated 
by a weak substance-P labeling (Miyamoto et al. 2019). 
Thus, the possible low proportion of D1 receptors in sub-
stance P-containing neurons could explain the lack of effect 
of the present pharmacological manipulations on phospho-
rylated DARPP-32 (Thr75). Taken together, these results 
suggest that there is a substantial action of TBZ on neurons 
containing D2 receptors (Nunes et al. 2013). Reductions 
in D2 receptor transmission have been shown to increase 
pDARRP-32(Thr34) and to decrease or show no change 
in pDARRP-32(Thr75) (Bateup et al. 2009; Bonito-Oliva 
et al. 2011; Nunes et al. 2013; Svenningsson et al. 2000). D2 
receptors are co-localized on enkephalin-containing medium 
spiny neurons (MSNs) (Svenningsson et al. 2000; Bateup 
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et al. 2009). In addition, in the present studies, bupropion 
was able to reverse the induction of pDARPP-32(Thr34) 
produced by TBZ, suggesting a predominant effect of both 
drugs on D2 receptors situated in striatal enkephalin-con-
taining MSNs.
In summary, our results demonstrated that bupropion 
increases the motivation to select highly active alternatives 
in choice situations, and to maintain activity under differ-
ent types of behavioral settings (stressful or reinforcing). 
Together with previous studies using different rodent and 
behavioral models (Randall et al. 2012, 2014, 2015; Yohn 
et al. 2015b, 2016b), our results also show how bupropion 
improves impaired behavior after injection of TBZ, and 
also increases exertion of physical effort when adminis-
tered alone (Randall et al. 2012, 2014, 2015). These results 
are supported by other studies in which bupropion was 
shown to exert its effects at doses that augment pre- and 
post-synaptic markers of DA transmission (Nunes et al. 
2013; Randall et al. 2015; Yohn et al. 2015b). Moreover, 
bupropion also has demonstrated to have therapeutic effects 
on motivational symptoms in humans (Papakostas et al. 
2006; Pae et al. 2007; Argyropoulos and Nutt 2013; Soskin 
et al. 2013), and the rank order of clinical effectiveness in 
depressed patients with psychomotor retardation paralleled 
the specificity of antidepressants as dopaminergic agents 
(Rampello et al. 1991; Brown and Gershon 1993; Tread-
way and Zald 2011; Treadway and Pizzagalli 2014). These 
motivational symptoms are not treated well by classical 
antidepressant drugs such as serotonin uptake inhibitors 
(Stahl 2002; Fava et al. 2014), which seem more effective 
in patients affected by anxious depression (Rampello et al. 
1995). Although repeated administration of antidepressants 
is commonly done in clinical practice, the present research 
used acute administration of bupropion, which is consistent 
with previous studies in rats (Nunes et al. 2013). In rodent 
studies, either acute or repeated administration of DA trans-
port inhibitors has been shown to be effective at enhancing 
selection of high effort instrumental actions (Randall et al. 
2015; Yohn et al. 2016c, d, e). Importantly, the use of acute 
administration of DA transport inhibitors to improve motiva-
tional function in rodents is consistent with human research 
reporting that acute administration of DA transport inhibi-
tors enhanced motivational function in depressed patients, 
with an onset of action within 2–3 h (Stotz et al. 1999).
This idea of different therapeutic drugs having positive 
actions for some symptoms, but no effect or even negative 
actions on other symptoms, is consistent with the research 
domain criterion (RDoC) approach (Cuthbert and Insel 
2013). In this sense, the present results also support the idea 
that alterations in dopaminergic transmission could contrib-
ute to the pathophysiology of motivational impairments in 
depression and other pathologies (Stahl 2002; Treadway and 
Zald 2011; Salamone et al. 2015), and they emphasize the 
recent theoretical approaches that take into consideration 
the diverse symptoms that patients with depression show, to 
create a more effective and individualized approach (Cuth-
bert and Insel 2013), encouraging investigators to use animal 
models for addressing neurobiological questions rather than 
as models of specific mental disorders (Molendijk and de 
Kloet 2021).
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